Jazz Pharmaceuticals (JAZZ) FY2016 results: revenue $1.5 billion, up 12.3% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $1.5 billion for fiscal 2016, the year ended 31 December 2016, up 12.3% on the year before. Net income was $397 million, up 20.4%, and diluted earnings per share $6.41. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2017.
Revenue
$1.5 billion
+12.3% on the year
FY2009FY2016
Operating margin
39.8%
38.4% a year earlier
FY2009FY2016
Net income
$397 million
+20.4% on the year
FY2009FY2016
Diluted EPS
$6.41
+22.6% on the year
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
1,488
1,325
1,173
+12.3%
Research and development
162
135
85.2
+20.0%
Selling, general and administrative
503
449
406
+12.0%
Operating income
592
508
196
+16.4%
Operating margin
39.8%
38.4%
16.7%
Interest expense
27.5
26.5
n/a
+3.8%
Pre-tax income
532
436
152
+22.1%
Income tax
135
106
94.2
+27.1%
Effective tax rate
25.4%
24.4%
62.2%
Net income
397
330
58.4
+20.4%
Net margin
26.7%
24.9%
5.0%
Diluted EPS
$6.41
$5.23
$0.93
+22.6%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
592
532
408
+11.4%
Capital expenditure
9.7
36.0
36.3
-73.1%
Free cash flow
583
496
371
+17.5%
Free cash flow margin
39.2%
37.4%
31.7%
Cash from investing
-1,749
-2.3
-1,068
Cash from financing
541
-214
711
Depreciation and amortisation
11.8
9.9
134
+19.2%
Share-based compensation
98.8
91.5
69.6
+7.9%
Buybacks
278
61.6
42.2
+352.1%
Diluted shares, weighted
62m
63m
63m
-1.8%
Shares outstanding at period end
60m
61m
61m
-2.4%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
1,877
1,599
1,371
+17.4%
Non-controlling interest
n/a
0.0
0.1
Debt
2,030
1,188
1,342
+70.8%
Other liabilities
893
546
625
+63.7%
Total liabilities and equity
4,800
3,333
3,339
+44.0%
Fixed assets
107
85.6
58.4
+25.6%
Goodwill
894
657
703
+36.0%
Intangible assets
3,012
1,186
1,437
+154.0%
Cash and equivalents
366
989
684
-63.0%
Receivables
234
210
186
+11.7%
Inventory
34.1
19.5
30.0
+75.1%
Other assets
153
186
240
-18.1%
Total assets
4,800
3,333
3,339
+44.0%
10-K for the year ended 31 December 2016, filed 28 February 2017: the filing.